A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial
about
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalizationLipids, statins, and clinical outcomes in heart failure: rethinking the data.Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial)Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HFPersistent pulmonary congestion before discharge predicts rehospitalization in heart failure: a lung ultrasound study.Use of tolvaptan vs. furosemide in older patients with heart failure : Meta-analysis of randomized controlled trials.Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: a meta-analysis of randomized controlled trials.Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy?Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/β-arrestin1/extracellular-regulated kinase 1/2-dependent pathway in H9c2 cells.Learning from recent trials and shaping the future of acute heart failure trials.Critical reappraisal of pulmonary artery catheterization and invasive hemodynamic assessment in acute heart failure.The vulnerable phase after hospitalization for heart failure.Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing.Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists.β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.Confounded by hospitalization: risk stratification and admission decisions in emergency department patients with acute heart failure.Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial.Chinese herbal injections for heart failure: A protocol for systematic review and network meta-analyses.Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER).Lessons learned in acute heart failure.Clinical trials in acute heart failure: beginning of the end or end of the beginning?Improving Postdischarge Outcomes in Acute Heart FailureRationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney diseaseInferior vena cava parameters predict re-admission in ischaemic heart failure
P2860
Q27025431-159E726A-B3EA-4EF6-B24B-83DF5F562B19Q30752824-01911B9E-1AA0-4F4E-89CA-60DE606CC6C7Q34152481-4D0954CD-42FB-4E32-921D-D1FF50B0A262Q34162275-71FEB0DE-D41C-4B35-B0C7-2BA4EF75C704Q35684955-E7AAE567-88C6-415A-BD1E-647CECB6C3C6Q36023194-F9295DB2-6174-406C-B90B-FA05EC2F7E0BQ36376174-9AE81400-BF35-45FA-85B7-1EA135000F52Q36511449-FC6B2383-5E62-416A-838F-4D3AC82C3D81Q36661094-00E0D001-2D8F-4DDF-9137-CA9D5FAD206EQ37027076-8D32B8F9-1DEA-4F59-88EC-6204F83A5D7DQ37531278-A03F6AA2-A486-400C-B4A2-F546593FDF78Q38097505-638BCB55-603F-4631-BAAF-2E1C43D1BE15Q38349760-30B31CF9-8A62-494F-948C-1C2A60793041Q38373981-7EB9EE0E-0F43-4CDF-812C-8298E9D33759Q38536675-CE6F3664-EB59-47B9-8023-E87D0FE1C6CEQ38957870-63272135-D3CD-42EA-B9B4-E26743889AC5Q39055218-2A5C2AEB-B2A8-4471-BB97-78B2D4C32215Q44672748-274E08F9-CE32-44D7-A190-E5103B8040B2Q45306207-3E1A49A3-079D-44AE-AF1B-6B73E005DD36Q46198550-81FB1FD5-00AE-4FE9-9DA3-895A3A9767FBQ49711896-218C4861-F9D7-49E9-A870-7211A77338E2Q51019622-A9B47A1C-752C-472E-8EF7-094C11F3B1B7Q52994251-A2B8F225-09E1-4D7D-9CD5-B30468921687Q53192175-C862303F-4433-43E5-AB2B-27744A547FCAQ57628371-673522A6-0D30-48D2-AC26-0781B220CAE3Q57911462-BD026FA4-10C0-4AAB-B7EB-1D75B920E8DDQ58197591-B7ECBBD6-A786-4C6A-85BE-183A7DD1B721
P2860
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial
description
article
@en
im September 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2011
@uk
name
A comprehensive, longitudinal ...... nalysis from the EVEREST trial
@en
A comprehensive, longitudinal ...... nalysis from the EVEREST trial
@nl
type
label
A comprehensive, longitudinal ...... nalysis from the EVEREST trial
@en
A comprehensive, longitudinal ...... nalysis from the EVEREST trial
@nl
prefLabel
A comprehensive, longitudinal ...... nalysis from the EVEREST trial
@en
A comprehensive, longitudinal ...... nalysis from the EVEREST trial
@nl
P2093
P2860
P50
P1476
A comprehensive, longitudinal ...... nalysis from the EVEREST trial
@en
P2093
Andrew P. Ambrosy
Brian Traver
Gloria Lan
James Udelson
John Burnett
Marvin Konstam
Philip Schmidt
Thomas Cook
P2860
P2888
P304
P356
10.1007/S10741-011-9280-0
P50
P577
2011-09-20T00:00:00Z